Purpose: We aimed to develop a gallium-68 (Ga-68)-labeled single-chain variable fragment (scFv) targeting the human epidermal growth factor receptor 2 (HER2) to rapidly and noninvasively evaluate the status of HER2 expression. Procedures: Anti-HER2 scFv was labeled with Ga-68 by using deferoxamine (Df) as a bifunctional chelate. Biodistribution of [
Introduction
T he human epidermal growth factor receptor 2 (HER2) is a member of ErbB family of receptor tyrosine kinases.
Excessive HER2 signaling due to receptor overexpression is a hallmark of a wide variety of solid tumors, such as breast, gastric, and ovarian carcinomas [1] [2] [3] . Although overexpression of HER2 is related to aggressiveness and poor prognosis, trastuzumab, a recombinant monoclonal antibody against HER2, has positively influenced the prognosis of patients with HER2-positive breast cancer [4] . Thus, accurate assessment of HER2 status is essential to select the patients who may benefit from the anti-HER2 therapy. HER2 status is routinely determined by immunohistochemistry and/or fluorescence in situ hybridization, by using biopsy specimens in clinical practice [5] . However, the HER2 status in the biopsy specimens is not always representative of the whole tumor because of sampling bias and intratumoral heterogeneity [6] . Moreover, a relatively high discordance in HER2 expression in primary versus metastatic lesions has been reported [7] , indicating a strong need for the reassessment of HER2 status associated with disease progression. Repetitive biopsy impairs the quality of life of the patients because of the invasiveness of the procedure.
Radionuclide molecular imaging of HER2 can help avoid biopsy-associated issues, because this technique is noninvasive, quantitative, and directed to the whole body [8] . Clinical studies employing positron emission tomography (PET) by using trastuzumab radiolabeled with copper-64 and zirconium-89 have been reported previously [9, 10] . Both probes visualized most of the known lesions and some that had been undetected earlier. These results indicate that nuclear medicine imaging of HER2 is effective, as expected. However, the large molecular weight of trastuzumab (148 kDa) leads to some imaging problems due to the long biodistribution time, slow tumor penetration, and slow blood clearance of the tracers, which in turn reduces target to nontarget contrast. Therefore, several types of radiolabeled trastuzumab fragments such as F(ab′) [11] , diabody [12] , and minibody [13] have been developed to fasten blood clearance and obtain successful HER2-positive tumor imaging. Nevertheless, there are no reports on the visualization of HER2-positive tumor in vivo by using radiolabeled singlechain Fv fragment (scFv).
Since scFv shows rapid distribution and clearance, radionuclides with short half-lives are preferable for radiolabeling to reduce the radiation exposure of patients. Gallium-68  Ga ]chelator. Although Df-conjugated antibody [15] and nanobody [16] have recently been reported, to the best of our knowledge, there has been no report on their application to scFv.
In this study, we developed [ 67/68 Ga]-labeled Df-anti-HER2 scFv to achieve faster blood clearance and better tumor-to-blood ratio at an early time point relative to that of trastuzumab. Furthermore, the changes in the expression l e v e l s o f H E R 2 a f t e r t r e a t m e n t w i t h 1 7 -dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), which destabilizes HER2 protein, were monitored by using this probe.
Experimental Procedures
Preparation of Deferoxamine-Conjugated Anti-HER2 scFv (Df-anti-HER2 scFv) and Nonradioactive Ga-Df-anti-HER2 scFv Anti-HER2 scFv (4D5-C10) with a COOH-terminal cysteine was a kind gift from CANON Inc. (Tokyo, Japan). The purity of anti-HER2 scFv (4D5-C10) was determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis and Coomassie staining. The p-isothiocyanatobenzyl derivative of deferoxamine (Df-p-SCN) was purchased from Macrocyclics, Inc. (Dallas, Tx).
The scFv was incubated with Df-p-SCN (3-fold molar equivalent, 12 μl in dimethyl sulfoxide) at 37°C for 30 min, in a total volume of 0.8 ml of 50 mM NaHCO 3 . Nonconjugated chelate was removed by size-exclusion chromatography using a PD-10 column (GE Healthcare Bio-Science AB, Uppsala, Sweden) with 0.25 M NaOAc (pH 5.5) as the eluent. The Df-anti-HER2 scFv was collected and concentrated by ultrafiltration (Amicon 10-kDa cutoff device; Millipore Corporation, Billerica, MA).
Nonradioactive GaCl 3 was added to 3 M NH 4 OAc to form Ga-acetate. Df-anti-HER2 scFv was incubated with Ga-acetate (10-fold molar equivalent, 7.3 μl in 3 M NH 4 OAc) at 37°C for 35 min, in a total volume of 0.5 ml of 0.25 M NaOAc (pH 5.5). Following purification using the PD-10 column, Ga-Df-anti-HER2 scFv was collected and concentrated by ultrafiltration.
The molecular weight of anti-HER2 scFv, Df-anti-HER2 scFv, and Ga-Df-anti-HER2 scFv was determined by matrixassisted laser desorption/ionization mass spectrometry (4800 Plus MALDI TOF/TOF™ Analyzer; AB SCIEX; Framingham, MA). was eluted from the generator and was concentrated using an anion exchange column (Chromafix, Macherey-Nagel GmbH & Co., Düren, Germany) [16] . The eluent from the anion exchange column was mixed with 3 M NH 4 OAc to facilitate 68 Ga]Df-anti-HER2 scFv was collected and used for further experiments. The radiochemical purity of the probes was determined by size-exclusion analysis using the PD-10 column. Size-exclusion high-performance liquid chromatography (SE-HPLC) was also performed (TSKgel SuperSW3000 [4.6×300 mm]; TOSOH Corporation, Tokyo, Japan; 100 mM phosphate buffer [pH 6.6] containing 0.1 M Na 2 SO 4 , 0.3 ml/min; wavelength 280 nm).
Preparation of [

In Vitro Stability
As described previously [17] with a slight modification, stability of [ 67 Ga]Df-anti-HER2 scFv was tested in 25 mM NaHCO 3 solution containing 5 mg/ml apo-transferrin. After incubation for 1, 2, 3, and 24 h at 37°C, 50 μl of the sample was collected for analysis by SE-HPLC. The eluent was collected every minute for 20 min and radioactivity was measured with an automatic well-type γ-counter (AccuFLEX γ7001B; Hitachi Aloka Medical, Ltd.; Tokyo, Japan). The retention time for apo-transferrin (80 kDa), chicken ovalbumin (44 kDa), anti-HER2 scFv (27 kDa), and horse myoglobin (17 kDa) was 12.1, 12.6, 13.3, and 14.0 min, respectively.
The stability of the probe in mouse plasma was also determined. Animal studies were conducted in accordance with our institutional guidelines, and the experimental procedures were approved by the Kyoto University Animal Care Committee. Female BALB/c mice (5 weeks, 17-18 g) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Blood was withdrawn from the hearts of euthanized mice (n=3) using heparinized syringes, and plasma was obtained by centrifugation at 1,000×g for 5 min at 4°C. [
67 Ga]Dfanti-HER2 scFv (20 μl) was incubated in mouse plasma (100 μl) for 1 h at 37°C, and then the sample was analyzed by SE-HPLC.
To determine the distribution ratio of [ 67 Ga]Df-anti-HER2 scFv in plasma and blood cells, the probe (20 μl) was incubated with mouse blood (200 μl) for 1 h at 37°C. After incubation, the blood was centrifuged at 1,000×g for 5 min at 4°C to separate plasma from blood cells. The radioactivity in each fraction was measured by the γ-counter.
Cells and Cell Culture
NCI-N87 human gastric cancer cells (N87) were obtained from American Type Culture Collection (Manassas, VA), and Suit-2 human pancreatic cancer cells were obtained from Human Science Research Resources Bank (Osaka, Japan). Both the cells were maintained in RPMI1640 medium supplemented with 10 % fetal bovine serum, 0.6 mg/ml Lglutamine, 1.8 mg/ml NaHCO 3 , 100 U/ml penicillin, and 100 mg/ml streptomycin.
Cell Binding Study
N87 cells were plated in a 24-well plate at 1×10 5 cells per well. After 18-h incubation, the culture medium was replaced by a medium containing 0.1-50 nM of 67 Ga-Dfanti-HER2 scFv and incubated for 2 h at 4°C. After the incubation, the medium was removed, and the cells were washed with phosphate-buffered saline (PBS) two times and lysed with 0.2 N NaOH. The radioactivity of each well was measured by γ-counter and was normalized using the protein concentration in each well, which was determined by using bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL). The equilibrium dissociation constant (K D ) was calculated using the GraphPad Prism software version 5.03 (GraphPad Software, Inc., La Jolla, CA).
Tumor Model
Female BALB/c nude mice (5 weeks, 18-22 g) were purchased from Japan SLC, Inc. N87, and Suit-2 cells (5× 10 6 cells each in 50 % Geltrex Matrix [Life Technologies Corporation, Carlsbad, CA] in PBS) were subcutaneously transplanted into the right and left shoulders of the mice, respectively [18] . The mice were subjected to a tracer study at 4-6 weeks after the implantation. Before use, the tumor size was measured using a caliper, and the volume was calculated using the following equation: tumor volume= length×(width) 2 /2 [19] . The average volume of N87 and Suit-2 xenografts was 150-250 mm 3 and 200-400 mm 3 , respectively.
Biodistribution Study
[ 67 Ga]Df-anti-HER2 scFv (30-50 kBq/0.81-1.35 μg, 100 μl in NaOAc buffer) was injected via the tail vein into the tumor-bearing mice (n=4-5); the mice were dissected at 1, 2, and 3 h after the injection. Whole organs were immediately obtained and weighed, and their radioactivity was measured. The results are expressed in terms of the percent injected dose per gram of the tissue (%ID/g).
Autoradiography and Immunohistochemistry
Tumor-bearing mice (n=2) received intravenous injection of [ 67 Ga]Df-anti-HER2 scFv (3.7 MBq). The mice were killed at 2 h after the injection, and the tumors were removed and frozen in hexane (−80°C). The frozen tumor samples were cut into 20-μm-thick sections and adjacent 10-μm-thick sections. After 2-day exposure, autoradiograms were obtained, according to a previously described method [20, 21] . The adjacent 10-μm sections were subjected to immunohistochemical analyses for HER2 by using HercepTest (Dako, Denmark). Immunostaining was performed as per the manufacturer's protocol.
PET Imaging
Tumor-bearing mice (n=2) were intravenously injected with [ 68 Ga]Df-anti-HER2 scFv (9-24 MBq/52-65 μg, 100 μl in NaOAc buffer). At 1, 2, and 3 h after injection, the mice were imaged for 20 min by using eXplore VISTA (GE Healthcare Bio-Science). The acquisition and reconstruction of images were performed according to a previously described method [22] . After PET imaging, the mice were euthanized at approximately 3.25 h postinjection. Tumors were immediately obtained and weighed, and their radioactivity was measured.
Treatment Protocol and In Vivo Monitoring of HER2 Expression
The mice (n=9) were used for therapeutic study when their tumor volume reached approximately 100-300 mm 3 . Animals were divided into three groups (three mice in each group). In one of the groups (vehicle-treated group), each animal received saline containing 10 % DMSO and 10 % ethanol, intravenously, once in a day for 3 consecutive days. The tumor size was monitored from day 0, when the animals received the 1st dose of treatment to day 14. In the other groups, a dose of 50 mg/kg of 17-DMAG dissolved in saline containing 10 % DMSO and 10 % ethanol was administered via tail vein injection for 3 consecutive days (a total of 150 mg/kg of 17-DMAG). The tumor size was monitored from day 0 to day 3 in one group and from day 0 to day 14 in the other groups. Tumor growth was monitored by caliper measurement, and tumor volume was calculated.
After the final measurement of tumor size in the 17-DMAG-treated groups, two mice from each group were subjected to PET/X-ray computed tomography (CT) imaging. The mice were intravenously injected with [ 68 Ga]Dfanti-HER2 scFv, and 2 h later, they were imaged for 20 min by using the FX3300 preclinical imaging system (Gamma Medica, Inc., Northridge, CA) under 2.5 % isoflurane anesthesia. Coincident data were collected for 511-keV gamma rays with an energy window of 250-700 keV. PET images were reconstructed by using a two-dimensional ordered-subset expectation maximization algorithm (iterations, 20; subsets, 4), and regions of interest (ROIs) were drawn on the tumors. CT scannings were performed according to a previously described method [23] . After PET/CT imaging, each tumor was removed and frozen for further analysis by using western blotting. Before freezing, the radioactivity and weight of the tumors were measured.
Western Blot
Tumors were homogenized in Passive Lysis Buffer (Promega Corporation, Madison, WI) with 1 % Protease Inhibitor Cocktail (Sigma-Aldrich, Inc., St. Louis, MO). The homogenates were centrifuged at 15,000×g for 10 min, and the supernatants were retained. The protein content was determined using the BCA protein assay kit. The supernatants were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis, and proteins were transferred to Immobilon PVDF membranes (Millipore Corporation, Billerica, MA). After blocking with Blocking One (Nacalai Tesque, Inc., Kyoto, Japan) for 30 min, the membranes were probed with HER2 antibody (#2242, Cell Signaling Technology, Inc., Danvers, MA) at 4°C for 12 h. After washing three times with PBS containing 0.05 % Tween20, antirabbit horseradish peroxidase-linked antibody (#7074, Cell Signaling Technology, Inc.) was allowed to react with the proteins at room temperature for 45 min. All the antibodies were diluted 1:1,000 with Can Get Signal (TOYOBO Co., Ltd., Osaka, Japan). After the washing step, the protein bands were visualized using Chemi-Lumi One Super (Nacalai Tesque, Inc.) with a gel imaging system (ChemiDoc XRS; Bio-Rad Laboratories, Hercules, CA). Immunoblotting with β-actin was used as a protein-loading control.
Statistical Analyses
Comparisons between the two groups were made using the Student's t test. The analyses of the data from the therapeutic study were performed using two-way analysis of variance (ANOVA) with repeated measures followed by a TukeyKramer multiple comparison test. A P value of G0.05 was considered statistically significant.
Results
Preparation of [ 67/68
Ga]Df-anti-HER2 scFv
The molecular weight of anti-HER2 scFv, Df-anti-HER2 scFv, and Ga-Df-anti-HER2 scFv was 27,609.2, 27,711.5, and 27,771.2, respectively. This result indicates that 0.14 Df was introduced into the scFv on the average and is in accordance with a previous report (0.2 Df per nanobody molecule) [16] .
The radiochemical yield of [ 67 Ga]Df-anti-HER2 scFv and [ 68 Ga]Df-anti-HER2 scFv was 83 and 86 %, respectively. The radiochemical purity of both the probes was greater than 98 %; its adsorption in PD-10 column was insignificant. [ 67 Ga]Df-anti-HER2 scFv was obtained in a single peak that corresponded to nonradioactive Ga-Df-anti-HER2 scFv by SE-HPLC.
Binding Affinity
The binding affinity of [
67 Ga]Df-anti-HER2 scFv was 9.94± 1.36 nM. This value represents the mean±standard deviation of three examinations and is within the optimal range (1-100 nM) at which significant tumor uptake is expected [24] .
In Vitro Stability
The temporal changes in intact [
67 Ga]Df-anti-HER2 scFv in apo-transferrin solution are shown in Table 1 . The radiochemical purity of [ 67 Ga]Df-anti-HER2 scFv was maintained at levels greater than 95 % after 3-h incubation with transferrin-containing NaHCO 3 solution. No radioactivity was eluted in the transferrin fractions. The recovery of radioactivity from the HPLC column was 92.6±6.4 %. After 24-h incubation, the purity decreased to 48.1 % and the recovery of radioactivity from the HPLC column was 77.5± 7.4 %, suggesting that low-molecular-weight by-products were generated during 24-h incubation.
In mouse plasma, [ 67 Ga]Df-anti-HER2 scFv was also stable. All radioactivity was eluted in the fraction of monomeric [
67 Ga]Df-anti-HER2 scFv after 1-h incubation in mouse plasma. The percentage of radioactivity distribution in plasma and blood cells was 84.4±1.0 and 15.6± 1.0 %, respectively.
Biodistribution Study
The results of biodistribution study are presented in Table 2 . The highest radioactivity was observed to accumulate in the kidneys. The radioactivity in blood at 1 h was higher than that in the tumors, but it decreased in a time-dependent manner. The radioactivity in N87 tumor increased in a timedependent manner and was the highest among that in all the organs examined at 3 h, except for the kidneys. Significantly high radioactivity accumulated in N87 xenograft compared to that in Suit-2 xenograft at 2 and 3 h postinjection. At 3 h postinjection, the ratios of N87 to blood, N87 to Suit-2, and N87 to muscle were 1.06±0.17, 1.97±0.24, and 7.92±5.57, respectively. Figure 1 shows the autoradiograms and the images of immunostained sections. Immunostaining revealed high expression of HER2 in the N87 xenograft but no expression in the Suit-2 xenograft. The radioactivity accumulated regions in N87 xenograft coincided with the HER2-positive regions. On the other hand, the radioactivity accumulation in Suit-2 xenograft was low and homogenous.
Autoradiography and Immunohistochemistry
PET Imaging
Decay-uncorrected, serial PET images are shown in Fig. 2 . N87 xenografts could be visualized in all the images, although radioactivity in the heart and liver was also high at 1 h postinjection, reflecting high radioactivity in blood. On the other hand, the radioactivity in Suit-2 xenografts was at background level at all the time points. The radioactivity in N87 and Suit-2 xenografts measured after dissection was 3.45 and 1.50 %ID/g, respectively. The ratio of N87 to Suit-2 was 2.30. 
Therapeutic Study
The effects of 17-DMAG on tumor growth and body weight are shown in Fig. 3 . 17-DMAG is an inhibitor of heat shock protein 90 (Hsp90) and is effective in many cancers [25] .
After treatment with 17-DMAG, the size of N87 xenograft initially decreased but increased again from day 5 onward. The growth of Suit-2 xenograft was delayed for 11 days. In contrast, both the xenografts in the vehicle-treated group continued to grow and increased in size by a factor of 2.5-4 by day 14 (Fig. 3a) . Two-way ANOVA demonstrated significant effects of the treatment (F 3, 48 =48.9; PG0.0001) and time (F 5, 48 = 39.3; P G0.0001), and a significant interaction between treatment and time (F 15, 48 =7.68; PG 0.0001) was observed. The size of N87 and Suit-2 xenografts in 17-DMAG-treated mice was significantly smaller than that of the vehicle-treated mice (PG0.01). The body weight was similar between the vehicle-and 17-DMAG-treated groups at any time point (Fig. 3b) . Figure 4 shows the images of PET and western blotting in the identical xenograft after treatment with 17-DMAG. We chose to perform PET images at 2 h postinjection because the effects of high background radioactivity and radioactive decay were more pronounced at 1 and 3 h postinjection, respectively. The N87 xenograft could be clearly observed in the control mouse, while the Suit-2 xenograft was not visible. On the day after 17-DMAG treatment was concluded (day 3), the tumor shrank and radioactivity accumulation, determined by the dissection method and PET imaging, was 33 and 31 %, respectively, as compared to that in control mice. Eleven days later (day 14), radioactivity accumulation, determined by the dissection method and PET imaging, was 66 and 75 %, respectively, compared to that in control mice (Fig. 4a) . These changes were in accordance with the changes in the expression of HER2 detected by western blotting. The signal density of HER2 normalized by β-actin was 29 and 76 % compared to that of the control mice on days 3 and 14, respectively (Fig. 4b) . There was no HER2 expression in the Suit-2 xenografts (data not shown).
Evaluation of HER2 Expression by PET Imaging and Western Blot Analysis
Discussion
Although trastuzumab and its fragmented derivatives have been labeled by various radionuclides [9, 10, 12, 13] , the pharmacokinetics of these probes was too slow to be labeled by short half-lived radionuclide, Ga-68. To our knowledge, there is only one report regarding [ 68 Ga]DOTA-conjugated antibody derivatives targeting HER2 [11] .
The authors developed [ 68 Ga]DOTA-F(ab′) 2 -Herceptin and succeeded in performing the PET imaging of HER2- Fig. 2 Representative PET images of N87-and Suit-2-implanted mice with 68 Ga-Df-anti-HER2 scFv. Images are shown at the same scale and not corrected by radioactive decay. Arrowheads and arrows indicate N87 and Suit-2 xenografts, respectively. expressing tumor in mice. However, the condition of radiolabeling was unclear. Neither temperature, reaction time, nor radiochemical yield was mentioned in the manuscript. In fact, the radiochemical yield of [ 68 Ga]DOTA-anti HER2 scFv was less than 5 % after 1-h incubation at room temperature in our preliminary experiment. On the other hand, rapid (G5 min) radiolabeling by Ga-67/68 was accomplished at room temperature with a high radiochemical yield (approximately 85 %) by using deferoxamine as a bifunctional chelating agent. Since the molecular size of scFv was smaller than that of F(ab′) 2 , [ 68 Ga]Df-anti-HER2 scFv showed faster blood clearance (scFv, 5.44 %ID/g at 3 h; F(ab′) 2 , 915 %ID/g at 3.5 h) and better tumor-to-blood ratio (scFv, 1.06 at 3 h; F(ab′) 2 , G1 at 3.5 h) than [ 68 Ga]DOTA-F(ab′) 2 -Herceptin did [11] . Recently, several protein-engineered, antibody-mimetic probes, called "affibody molecules," have been developed and labeled with Ga-68 to target and image HER2. Among them, one of the most promising probes is [ 68 Ga]ABY-002, which was used in humans for the first time and was successfully employed for imaging HER2-expressing tumors in breast cancer patients [26] . In preclinical experiment, [ 68 [28, 29] . However, both affibody probes showed better tumor-to-blood ratio than [ 68 Ga]Df-anti-HER2 scFv. Therefore, structural modification of [ 68 Ga]Df-anti-HER2 scFv is required to improve the blood ratio.
Although [ 68 Ga]Df-anti-HER2 scFv showed faster blood clearance than radiolabeled trastuzumab and its fragmented derivative, the radioactivity of [ 68 Ga]Df-anti-HER2 scFv in blood was higher than those of the other scFv probes [30, 31] . Gallium is reported to form a complex with transferrin, which exists in blood [32] Ga]-nanobody probe previously reported in human serum, using the same bifunctional chelating agent as in the present study [16] . Thus, slow blood clearance is not attributable to a transchelation reaction with transferrin followed by circulation of 68 Ga- [33, 34] . Thus, the radioactivity ratios of tumor to thoracic and abdominal organs are important to evaluate HER2 expression by using [ 68 Ga]Df-anti-HER2 scFv. The biodistribution study indicated that the highest radioactivity accumulated in the kidneys. Although tumorto-stomach ratio was greater than 1, the high radioactivity in the kidneys may hamper the application of [ 68 Ga]Df-anti-HER2 scFv for metastatic gastric cancer. However, it would interfere the least with the imaging quality of breast cancer, which is distant from the kidneys. Since the ratios of tumor to heart and lung were greater than 1 after 2 h postinjection, [ 68 Ga]Df-anti-HER2 scFv was capable of monitoring the HER2 expression of breast cancer noninvasively.
In PET study, the protein concentration of [ 68 Ga]Df-anti-HER2 scFv was approximately 50-fold higher than that of [ 67 Ga]Df-anti-HER2 scFv used for the biodistribution study. Although the tumoral accumulation of [ 68 Ga]Df-anti-HER2 scFv in PET study was lower than that in biodistribution study, the radioactivity ratio of HER2-positive to HER2-negative xenografts was comparable in both the studies. Thus, the difference in the specific activity of the probe probably did not affect the probe distribution. Specific activity of [ 68 Ga]Df-anti-HER2 scFv used for PET study (0.2-0.4 MBq/μg) was comparable to that of other [
68 Ga]- labeled probes (0.4-0.6 MBq/μg) that were successful in PET imaging of HER2-positive xenografts [27, 28] . Reduction of blood flow under anesthesia may cause low accumulation of [ 68 Ga]Df-anti-HER2 scFv in PET study. Hsp90 is a molecular chaperone that plays an important role in the maturation and stability of client proteins. Since HER2 is one of the most sensitive target proteins of Hsp90, it is expected that the Hsp90 inhibitors would be effective against HER2-overexpressing tumors [35] . Therefore, we used 17-DMAG for anti-HER2 therapy, which is the first Hsp90 inhibitor approved for clinical trials [36] , and succeeded in monitoring HER2 status after therapy by noninvasive PET imaging. Chandarlapaty et al. reported that combined therapy of trastuzumab and a Hsp90 inhibitor was effective for treating trastuzumab-resistant breast cancer [37] , and phase I dose-escalation clinical trial of trastuzumab and 17-DMAG was recently performed [38] . Since the anti-HER2 scFv used in this study recognizes the same epitope as trastuzumab, the monitoring of HER2 status during the combination therapy is unfortunately difficult. Affibodybased probes can overcome this issue because they bind to distinct epitopes on the HER2 extracellular domain, which is different from the binding site of trastuzumab [39] .
Conclusion
By using deferoxamine as a bifunctional chelate, [ 68 Ga]-labeled scFv targeting HER2 was rapidly obtained under mild labeling conditions. [ 68 Ga]Df-anti-HER2 scFv maintained its immunoreactivity and showed high accumulation in HER2-positive xenografts. The intratumoral distribution of radioactivity coincided with HER2-positive regions. Although low tumor-to-blood ratio needs to be improved, [ 68 Ga]Df-anti-HER2 scFv successfully visualized HER2-positive xenografts and monitored the changes in HER2 expression after therapy. Thus, [ 68 Ga]Df-anti-HER2 scFv could be a promising probe to evaluate HER2 status by in vivo PET imaging, unless trastuzumab is prescribed as part of the therapy.
